Tirofiban Discontinuation After Ticagrelor Loading
Stop the tirofiban infusion 2 hours after administering the ticagrelor loading dose. 1
Rationale and Clinical Context
When transitioning from intravenous GP IIb/IIIa inhibitor therapy (tirofiban/Aggrastat) to oral P2Y12 inhibitor therapy (ticagrelor), the key consideration is ensuring adequate platelet inhibition while minimizing bleeding risk.
Pharmacodynamic Overlap Strategy
Ticagrelor achieves >90% platelet inhibition within approximately 2 hours of the 180 mg loading dose 2. This rapid onset allows for safe discontinuation of tirofiban shortly after oral therapy is initiated.
The evidence-based approach from contemporary practice demonstrates:
- Give ticagrelor 180 mg loading dose first
- Continue tirofiban infusion for 2 hours post-loading
- Then discontinue tirofiban 1
This 2-hour overlap ensures continuous platelet inhibition during the transition period, as ticagrelor reaches therapeutic levels while tirofiban's effect wanes.
Supporting Evidence from Guidelines
The ACC/AHA guidelines specify that tirofiban infusions should be continued "up to 18 hours at the discretion of the physician" in the context of PCI 3, 4, 5. However, when transitioning to potent oral P2Y12 inhibitors, earlier discontinuation is appropriate once adequate oral antiplatelet effect is established.
For urgent CABG planning: Short-acting IV GP IIb/IIIa receptor antagonists (including tirofiban) should be discontinued at least 2-4 hours before surgery 6, demonstrating the drug's relatively short duration of action.
Pharmacokinetic Considerations
Tirofiban has a half-life of approximately 2 hours, with platelet aggregation returning to near baseline in 4-8 hours after discontinuation in approximately 90% of patients 7. This short half-life supports the safety of early discontinuation once oral therapy is on board.
Common Pitfalls to Avoid
- Don't stop tirofiban immediately upon giving ticagrelor—allow the 2-hour window for ticagrelor to reach therapeutic levels
- Don't continue tirofiban unnecessarily long once ticagrelor is therapeutic, as this increases bleeding risk without additional benefit
- Monitor for bleeding during the transition period, as dual antiplatelet therapy with GP IIb/IIIa inhibitors increases hemorrhagic risk 7
Clinical Context from Real-World Practice
A case series specifically addressing this transition demonstrated successful outcomes using tirofiban infusion started 2 hours post-intervention, followed by ticagrelor 180 mg loading, with tirofiban discontinued 2 hours after the ticagrelor bolus 1. This approach maintained platelet inhibition without excessive bleeding.